Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimal-flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
NCT06521697Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Sponsor
- National Taiwan University Hospital
- Modality
- Small Molecules
- Conditions
- acute kidney injury (AKI)pain
01
Overview
Phase 4, randomised trial of dexmedetomidine, ketamine and lidocaine in acute kidney injury (AKI) and pain (4 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Sevoflurane usage and Renal function changes. Planned start Aug 2024; status: not yet recruiting.
02
Design
4 arms- Study design
- Randomized
HL-D
Minimal flow (0.5 L/min) + DKL mixture
HL-ND
Minimal flow (0.5 L/min) + Placebo
L-D
Low flow (1.0 L/min) + DKL mixture
L-ND
Low flow (1.0 L/min) + Placebo
03
Who it enrols
Adult patients scheduled for head and neck cancer tumor resection and free flap reconstruction, excluding those with severe renal, cardiac, or hepatic impairment, anemia, or specific medication use.
04
Endpoints
Primary
Sevoflurane usage
Renal function changes
Secondary
Incidence of acute kidney injury
Hemodynamic stability
Postoperative analgesic effect
Length of hospital stay
Postoperative cognitive function
Beyond the preview
Go deeper on NCT06521697.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521697.